Effects of F17464 in acute exacerbation of schizophrenia
Effects of F17464 in acute exacerbation of schizophrenia
F17464 in Acute Schizophrenia Trial
Effects of F17464 in acute exacerbation of schizophrenia
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
65
Years old
Gender
All
Therapeutic area :
Psychiatry
Disease :
Schizophrenia
Study medication :
F17464
Phase :
Phase II
Start Date :
20 August 2014
End date :
23 November 2016
Study ID :
F17464 GE 201
EudraCT/CTIS number :
2013-005451-32
CT.gov Number :
NCT02151656
Send by email